The Research Of Protective Effects Of Probiotics On Intestinal Mucosal Barrier In Rats With Hepatic Fibrosis

Background:The patients with cirrhosis clinically are often accompanied by intestinal endotoxemia, and intestinal mucosal barrier injury is a key part of the formation of intestinal endotoxemia. Mentor Liu Lixin preliminary study found that hepatic fibrosis in rats induced by thioacetamide associated with the intestinal endotoxemia, so we use thioacetamide making the hepatic fibrosis model in rats. The probiotics Bifico is triple viable preparation of Bifidobacterium, Lactobacillus and Streptococcus, currently widely used in clinical treatment of acute and chronic diarrhea caused by imbalance of intestinal flora, and in patients with cirrhosis role of adjuvant therapy. In this study, Bifico is the positive control drug.Bacillus licheniformis is a new probiotic preparation, developed first in China, commonly used in clinical intestinal disorders caused by imbalance of intestinal flora, such as acute and chronic diarrhea, flatulence, dyspepsia and so on. Wheather Bacillus licheniformis could pretect intestinal mucosal barrier in rats with hepatic fibrosis, the current reports have not seen. Therefore, the subject is designed.Objective:To identify the protection effect of Bacillus licheniformis on intestinal mucosal barrier in rats with hepatic fibrosis, and effects on intestinal endotoxemia and hepatic fibrosis.Methods:Forty male normal SD rats were randomly into five group(8rats for each group). They were normal control group(A), model group(B), Bifico group(C), low-dose Bacillus licheniformis group(D)and high-dose Bacillus licheniformis group(E). Nothing be done in group A. Thioacetamide of100mg/kg was injected into subcutaneous for nine consecutive weeks by three times per week in group B. In group C, the thioacetamide usage with group B, the Bifico was gavaged once every day by2ml per rat(35ml/ml)for seven consecutive weeks. In group D, the thioacetamide usage with group B, the Bacillus licheniformis was gavaged once every day by5mg/mg for seven consecutive weeks. In group E, the thioacetamide usage with group B, the Bacillus licheniformis was gavaged once every day by15mg/mg for seven consecutive weeks. All rats were under ether anesthesia after nine weeks, the blood was extracted from abdominal aorta under sterile and pyrogen-free. The blood levels of endotoxin, ALT, AST, LDH, MDA and DAO were determined. Liver and ileal tissue were stained by HE after soaked with10%neutral buffered formalin. Ileal tissue were stained by toluidine blue after soaked with10%neutral buffered formalin.Results:1. Results of the blood parameters:Compared with normal control group, the blood levels of endotoxin, ALT, AST, LDH, MDA and DAO in group B were higher(P<0.01). Compared with model group, the blood level of ALT in group C were lower(P<0.01), the blood levels of endotoxin, AST, LDH, MDA and DAO in group C, D and E were lower(P<0.01). Compared with normal control group, the blood levels of endotoxin and ALT in group E were higher(P<0.01), the difference was statistically.2. The HE and toluidine blue staining results:The pathological damages of liver and ileal tissue in group C, D and E were obviously milder than that in model group, and the number of intestinal mucosal mast cells and degranulation were less than those in model group.Conclusion:1. Bacillus licheniformis could protect intestinal mucosal barrier in rats with hepatic fibrosis, this role is achieved by alleviating the pathological changes of the intestinal mucosal, reducing the number of intestinal mucosal mast cells and degranulation, and reducing the blood level of DAO.2. Bacillus licheniformis could improve intestinal endotoxemia and hepatic fibrosis, this role is achieved by reducing the blood levels of endotoxin, ALT, AST, LDH and reducing oxidative damage.